Revitope Oncology
San Francisco
About Revitope Oncology
Revitope is developing a novel approach to cancer immunotherapy. Cancer patients typically have strong cytotoxic immunity against viral pathogens while lacking immunity against their tumors. Revitope’s technology redirects an exisiting viral immune response to treat cancer. Revitope’s antibody peptide epitope complex (APEC) technology selectively delivers an immunodominant viral peptide to the tumor cell, thereby activating exisiting T cells that recognize the tumor as virally infected, and kill it.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $8.5M
- Last round: Series Unknown (Feb 2016)
- Website: revitope.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/revitope-oncology-134209 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.